Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28643739 | 0.83 | ALDH1A1 (0.40) | MEN1KMT2ALMNASMN1; SMN2TSHR | |
| SCHEMBL8960045 | 0.81 | KDM4E (0.49) | F3DRD2DRD1MEN1KMT2A | |
| SCHEMBL11626560 | 0.78 | ALDH1A1 (0.49) | F3DRD2DRD1MEN1KMT2A | |
| SCHEMBL5900986 | 0.77 | MEN1 (0.40) | MEN1KMT2AGBA1LMNAALDH1A1 | |
| SCHEMBL11727721 | 0.76 | POLB (0.44) | GBA1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4127686 | 0.74 | ADRA1A (0.39) | MEN1KMT2ALMNAALDH1A1HPGD | |
| SCHEMBL7270589 | 0.74 | CA12 (0.50) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL11722874 | 0.73 | MAPT (0.49) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7675302 | 0.73 | MEN1 (0.41) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4128903 | 0.73 | CETP (0.48) | F3DRD2DRD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | PINNEY KEVIN G | 2006-06-29 | — | — | US | disclosed |
| US-7001926-B2 | Tubulin binding agents and corresponding prodrug constructs | OXIGENE, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2004087061-A2 | TUBULIN BINDING AGENTS AND CORRESPONDING PRODRUG CONSTRUCTS | OXIGENE, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | F3 1427/4885DRD2 4064/4885DRD1 4218/4885 |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | F3 1427/4885DRD2 4064/4885DRD1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.